ZA200703396B - Pegylated Liposomal Doxorubicin in combination with Ecteinascidin 743 - Google Patents

Pegylated Liposomal Doxorubicin in combination with Ecteinascidin 743

Info

Publication number: ZA200703396B
Authority: ZA; South Africa
Prior art keywords: combination; ecteinascidin; pegylated liposomal; liposomal doxorubicin; therapeutic amount
Prior art date: 2004-10-26

Application number

ZA200703396A

Other languages

English (en)

Inventor

Gilles Erard

Trifan Ovid

Teitelbaum April

Sternas Lars-Axel

Van De Velde Helgi

Original Assignee

Pharma Mar S A Soc Uniplersona

Ortho Biotech Products L P

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-26

Filing date

2007-04-25

Publication date

2008-11-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36096124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200703396(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-04-25 Application filed by Pharma Mar S A Soc Uniplersona, Ortho Biotech Products L P filed Critical Pharma Mar S A Soc Uniplersona

2008-11-26 Publication of ZA200703396B publication Critical patent/ZA200703396B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

ZA200703396A 2004-10-26 2007-04-25 Pegylated Liposomal Doxorubicin in combination with Ecteinascidin 743 ZA200703396B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US62216304P	2004-10-26	2004-10-26

Publications (1)

Publication Number	Publication Date
ZA200703396B true ZA200703396B (en)	2008-11-26

Family

ID=36096124

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200703396A ZA200703396B (en)	2004-10-26	2007-04-25	Pegylated Liposomal Doxorubicin in combination with Ecteinascidin 743

Country Status (27)

Country	Link
US (1)	US20090117176A1 (da)
EP (1)	EP1827500B1 (da)
JP (2)	JP4554684B2 (da)
KR (1)	KR101287918B1 (da)
CN (1)	CN101119750B (da)
AT (1)	ATE430586T1 (da)
AU (1)	AU2005298364B2 (da)
BR (1)	BRPI0518250A2 (da)
CA (1)	CA2582452C (da)
CY (1)	CY1110329T1 (da)
DE (1)	DE602005014380D1 (da)
DK (1)	DK1827500T3 (da)
ES (1)	ES2326825T3 (da)
HK (1)	HK1107766A1 (da)
HR (1)	HRP20090345T1 (da)
IL (1)	IL182352A (da)
MX (1)	MX2007004744A (da)
NO (1)	NO328958B1 (da)
NZ (1)	NZ554765A (da)
PL (1)	PL1827500T3 (da)
PT (1)	PT1827500E (da)
RS (1)	RS50822B (da)
RU (1)	RU2359700C2 (da)
SI (1)	SI1827500T1 (da)
UA (1)	UA87877C2 (da)
WO (1)	WO2006046080A2 (da)
ZA (1)	ZA200703396B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY164077A (en)	1999-05-13	2017-11-30	Pharma Mar Sa	Compositions and uses of et743 for treating cancer
MXPA02011319A (es)	2000-05-15	2003-06-06	Pharma Mar Sa	Analogos antitumorales de ecteinascidina 743.
ATE495793T1 (de) *	2000-11-06	2011-02-15	Pharma Mar Sa	Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
GB0117402D0 (en) *	2001-07-17	2001-09-05	Pharma Mar Sa	New antitumoral derivatives of et-743
GB0202544D0 (en)	2002-02-04	2002-03-20	Pharma Mar Sa	The synthesis of naturally occuring ecteinascidins and related compounds
RS50692B (sr)	2003-11-13	2010-06-30	Pharma Mar S.A.U.	Kombinacija et-743 sa prolekovima 5-fluorouracila za lečenje kancera
US20080255132A1 (en) *	2003-11-14	2008-10-16	Eric Rowinsky	Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
ES2290844T3 (es)	2004-10-29	2008-02-16	Pharma Mar S.A., Sociedad Unipersonal	Composiciones que comprenden ecteinascidinas y un disacarido.
GB0522082D0 (en)	2005-10-31	2005-12-07	Pharma Mar Sa	Formulations
CN101489593B (zh)	2006-06-19	2015-11-25	约翰·霍普金斯大学	通过脂质体酶的治疗剂肿瘤特异性递送
JP2011500046A (ja) *	2007-10-19	2011-01-06	ファルマ・マール・ソシエダード・アノニマ	Ｅｔ−７４３治療のための予後分子マーカー
EP3518931A4 (en) *	2016-09-27	2020-05-13	Vertex Pharmaceuticals Incorporated	Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors
JOP20190254A1 (ar)	2017-04-27	2019-10-27	Pharma Mar Sa	مركبات مضادة للأورام
RU2657835C1 (ru) *	2017-11-28	2018-06-15	Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС"	Способ получения системы для доставки противоопухолевого препарата в клетки опухоли

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5149804A (en) *	1990-11-30	1992-09-22	The Board Of Trustees Of The University Of Illinois	Ecteinascidins 736 and 722
US5256663A (en) *	1986-06-09	1993-10-26	The Board Of Trustees Of The University Of Illinois	Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) *	1986-06-09	1992-02-18	Board Of Trustees Of The University Of Illinois	Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3635711A1 (de) *	1986-10-21	1988-04-28	Knoll Ag	5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) *	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) *	1993-12-02	1995-12-26	The Board Of Trustees Of The University Of Illinois	Ecteinascidins
US20040059112A1 (en) *	1994-02-18	2004-03-25	Rinehart Kenneth L.	Ecteinascidins
GB9508195D0 (en) *	1995-04-20	1995-06-07	Univ British Columbia	Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) *	1996-09-18	1998-02-24	President And Fellows Of Harvard College	Process for producing ecteinascidin compounds
US5985876A (en) *	1997-04-15	1999-11-16	Univ Illinois	Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
US6124293A (en) *	1998-04-06	2000-09-26	The Board Of Trustees Of The University Of Illinois	Semi-synthetic ecteinascidins
US6124292A (en) *	1998-09-30	2000-09-26	President And Fellows Of Harvard College	Synthetic analogs of ecteinascidin-743
MY164077A (en) *	1999-05-13	2017-11-30	Pharma Mar Sa	Compositions and uses of et743 for treating cancer
AR035842A1 (es) *	1999-05-14	2004-07-21	Pharma Mar Sa	Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
US20020028237A1 (en) *	2000-04-20	2002-03-07	Colbern Gail T.	Method for reducing toxicity of a cytotoxic agent
US7247892B2 (en) *	2000-04-24	2007-07-24	Taylor Geoff W	Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) *	2000-05-15	2008-09-02	Pharma Mar, S.A.	Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) *	2000-05-15	2003-06-06	Pharma Mar Sa	Analogos antitumorales de ecteinascidina 743.
EP1356097A2 (en) *	2000-08-11	2003-10-29	City of Hope	The anti-neoplastic agent et-743 inhibits trans activation by sxr
CZ20031211A3 (cs) *	2000-10-31	2003-09-17	Pharma Mar, S. A.	Prostředek kahalalid F, souprava a použití při léčbě karcinomů
ATE495793T1 (de) *	2000-11-06	2011-02-15	Pharma Mar Sa	Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
KR20030081496A (ko) *	2001-03-06	2003-10-17	브리스톨-마이어스 스큅 컴퍼니	테가푸르, 우라실, 폴린산, 파클리탁셀 및 카르보플라틴투여를 통한 종양 치료 방법 및 이들의 투여 형태
MXPA03011593A (es) *	2001-06-15	2005-03-07	Cornestone Pharmaceuticals	Composiciones farmaceuticas y de diagnostico que contienen nanoparticulas utilies para tratar tejidos y celulas blanco.
EP1435988A4 (en) *	2001-10-19	2008-01-09	Pharmamar Sa	IMPROVED USE OF ANTI-TUMORAL COMPOUND IN THE TREATMENT OF CANCER
US20040019027A1 (en) *	2002-04-12	2004-01-29	Barry Forman	Method of treating cerebrotendinous xanthomatosis
AU2003253954A1 (en) *	2002-07-16	2004-02-02	Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California	Support bra for ultrasonic breast scanner
GB0312407D0 (en) *	2003-05-29	2003-07-02	Pharma Mar Sau	Treatment
GB0324201D0 (en) *	2003-10-15	2003-11-19	Pharma Mar Sau	Improved antitumoral combinations
RS50692B (sr) *	2003-11-13	2010-06-30	Pharma Mar S.A.U.	Kombinacija et-743 sa prolekovima 5-fluorouracila za lečenje kancera
US20080255132A1 (en) *	2003-11-14	2008-10-16	Eric Rowinsky	Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
GB0326486D0 (en) *	2003-11-14	2003-12-17	Pharma Mar Sau	Combination treatment
US20050129752A1 (en) *	2003-12-15	2005-06-16	Tty Biopharm Limited Company	Use and manufacturing process for liposomal doxorubicin pharmaceutical composition
WO2006005602A2 (en) *	2004-07-09	2006-01-19	Pharma Mar, S.A.	Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
ES2290844T3 (es) *	2004-10-29	2008-02-16	Pharma Mar S.A., Sociedad Unipersonal	Composiciones que comprenden ecteinascidinas y un disacarido.
WO2007062413A2 (en) *	2005-11-25	2007-05-31	University Of Medicine And Dentistry Of New Jersey	Use of parp-1 inhibitors
US20080075772A1 (en) *	2006-04-13	2008-03-27	Lawrence Solomon	Pharmaceutical compositions having novel scoring patterns and methods of using those compositions
MX2008014404A (es) *	2006-05-12	2008-11-27	Pharma Mar Sa	Tratamientos anticancer con combinacion de docetaxel y ecteinascidin.

2005
- 2005-10-26 ES ES05803151T patent/ES2326825T3/es active Active
- 2005-10-26 SI SI200530688T patent/SI1827500T1/sl unknown
- 2005-10-26 PL PL05803151T patent/PL1827500T3/pl unknown
- 2005-10-26 AT AT05803151T patent/ATE430586T1/de active
- 2005-10-26 US US11/577,790 patent/US20090117176A1/en not_active Abandoned
- 2005-10-26 CN CN2005800369316A patent/CN101119750B/zh active Active
- 2005-10-26 WO PCT/GB2005/050189 patent/WO2006046080A2/en active Application Filing
- 2005-10-26 EP EP05803151A patent/EP1827500B1/en not_active Revoked
- 2005-10-26 DE DE602005014380T patent/DE602005014380D1/de active Active
- 2005-10-26 PT PT05803151T patent/PT1827500E/pt unknown
- 2005-10-26 RS RSP-2009/0311A patent/RS50822B/sr unknown
- 2005-10-26 BR BRPI0518250-6A patent/BRPI0518250A2/pt not_active Application Discontinuation
- 2005-10-26 MX MX2007004744A patent/MX2007004744A/es active IP Right Grant
- 2005-10-26 AU AU2005298364A patent/AU2005298364B2/en active Active
- 2005-10-26 CA CA2582452A patent/CA2582452C/en active Active
- 2005-10-26 RU RU2007119545/14A patent/RU2359700C2/ru active
- 2005-10-26 KR KR1020077009355A patent/KR101287918B1/ko active Active
- 2005-10-26 NZ NZ554765A patent/NZ554765A/en unknown
- 2005-10-26 DK DK05803151T patent/DK1827500T3/da active
- 2005-10-26 UA UAA200705818A patent/UA87877C2/ru unknown
- 2005-10-26 JP JP2007538524A patent/JP4554684B2/ja active Active
2007
- 2007-04-01 IL IL182352A patent/IL182352A/en active IP Right Grant
- 2007-04-25 ZA ZA200703396A patent/ZA200703396B/xx unknown
- 2007-05-16 NO NO20072543A patent/NO328958B1/no unknown
2008
- 2008-01-22 HK HK08100804.8A patent/HK1107766A1/xx unknown
2009
- 2009-06-15 HR HR20090345T patent/HRP20090345T1/xx unknown
- 2009-08-03 CY CY20091100818T patent/CY1110329T1/el unknown
- 2009-09-24 JP JP2009219607A patent/JP2009292850A/ja active Pending

Also Published As

Publication number	Publication date
JP4554684B2 (ja)	2010-09-29
AU2005298364B2 (en)	2009-03-26
RU2359700C2 (ru)	2009-06-27
ATE430586T1 (de)	2009-05-15
KR101287918B1 (ko)	2013-07-19
IL182352A0 (en)	2007-07-24
CA2582452C (en)	2010-09-07
HRP20090345T1 (en)	2009-08-31
CA2582452A1 (en)	2006-05-04
PT1827500E (pt)	2009-08-05
PL1827500T3 (pl)	2009-09-30
CN101119750A (zh)	2008-02-06
AU2005298364A1 (en)	2006-05-04
US20090117176A1 (en)	2009-05-07
RU2007119545A (ru)	2008-12-10
JP2009292850A (ja)	2009-12-17
CN101119750B (zh)	2013-03-06
SI1827500T1 (sl)	2009-10-31
MX2007004744A (es)	2007-10-23
EP1827500B1 (en)	2009-05-06
IL182352A (en)	2016-07-31
HK1107766A1 (en)	2008-04-18
DK1827500T3 (da)	2009-08-31
CY1110329T1 (el)	2015-01-14
BRPI0518250A2 (pt)	2008-11-11
NO328958B1 (no)	2010-06-28
UA87877C2 (en)	2009-08-25
WO2006046080A3 (en)	2006-10-19
RS50822B (sr)	2010-08-31
EP1827500A2 (en)	2007-09-05
ES2326825T3 (es)	2009-10-20
WO2006046080A2 (en)	2006-05-04
JP2008517991A (ja)	2008-05-29
NO20072543L (no)	2007-07-13
KR20070108135A (ko)	2007-11-08
WO2006046080A8 (en)	2007-07-12
NZ554765A (en)	2010-01-29
DE602005014380D1 (de)	2009-06-18

Publication	Publication Date	Title
ZA200703396B (en)	2008-11-26	Pegylated Liposomal Doxorubicin in combination with Ecteinascidin 743
IL273765A (en)	2020-05-31	Combinations and forms of administration of therapeutic agents and combined treatment
WO2001066123A3 (en)	2004-01-08	Composition consisting of phy906 and chemotherapeutic agents
WO2004103301A3 (en)	2005-11-03	Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
HRP20080598T3 (en)	2009-01-31	Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
NZ525730A (en)	2004-12-24	Compositions for antitumour treatments containing Ecteinascidin 743
WO2007134203A3 (en)	2008-05-29	Anticancer treatments with a combination of docetaxel and ecteinascidin
AU4789099A (en)	2000-02-07	Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents
TW200633700A (en)	2006-10-01	Methods of using temozolomide formulation intrathecally in the treatment of cancers
AUPR227100A0 (en)	2001-01-25	Composition for use in the treatment of patients with kidney stones